---
title: 'L-RNA aptamer-based CXCL12 inhibition combined with radiotherapy in newly-diagnosed
  glioblastoma: dose escalation of the phase I/II GLORIA trial'
date: '2024-05-28'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38806504/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20240529181135&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: The chemokine CXCL12 promotes glioblastoma (GBM) recurrence after radiotherapy
  (RT) by facilitating vasculogenesis. Here we report outcomes of the dose-escalation
  part of GLORIA (NCT04121455), a phase I/II trial combining RT and the CXCL12-neutralizing
  aptamer olaptesed pegol (NOX-A12; 200/400/600 mg per week) in patients with incompletely
  resected, newly-diagnosed GBM lacking MGMT methylation. The primary endpoint was
  safety, secondary endpoints included maximum tolerable dose ...
disable_comments: true
---
The chemokine CXCL12 promotes glioblastoma (GBM) recurrence after radiotherapy (RT) by facilitating vasculogenesis. Here we report outcomes of the dose-escalation part of GLORIA (NCT04121455), a phase I/II trial combining RT and the CXCL12-neutralizing aptamer olaptesed pegol (NOX-A12; 200/400/600 mg per week) in patients with incompletely resected, newly-diagnosed GBM lacking MGMT methylation. The primary endpoint was safety, secondary endpoints included maximum tolerable dose ...